Park JW - Search Results

1

Expression profiling of circulating tumor cells in metastatic breast cancer.

Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman LJ, Tripathy D, van 't Veer L, Park JW. Lang JE, et al. Among authors: park jw. Breast Cancer Res Treat. 2015 Jan;149(1):121-31. doi: 10.1007/s10549-014-3215-0. Epub 2014 Nov 29. Breast Cancer Res Treat. 2015. PMID: 25432738 Free PMC article. Clinical Trial.

2

MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer.

Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. Esserman L, et al. Ann Surg Oncol. 2001 Jul;8(6):549-59. doi: 10.1007/s10434-001-0549-8. Ann Surg Oncol. 2001. PMID: 11456056

3

Liposome-based drug delivery in breast cancer treatment.

Park JW. Park JW. Breast Cancer Res. 2002;4(3):95-9. doi: 10.1186/bcr432. Epub 2002 Apr 18. Breast Cancer Res. 2002. PMID: 12052251 Free PMC article. Review.

4

Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma.

Rini BI, Weinberg V, Shaw V, Scott J, Bok R, Park JW, Small EJ. Rini BI, et al. Among authors: park jw. Cancer. 2004 Jul 1;101(1):90-5. doi: 10.1002/cncr.20313. Cancer. 2004. PMID: 15221993 Free article. Clinical Trial.

5

Immune dysfunction and micrometastases in women with breast cancer.

Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ. Campbell MJ, et al. Among authors: park jw. Breast Cancer Res Treat. 2005 May;91(2):163-71. doi: 10.1007/s10549-004-7048-0. Breast Cancer Res Treat. 2005. PMID: 15868444

6

Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer.

Garcia JA, Rosenberg JE, Weinberg V, Scott J, Frohlich M, Park JW, Small EJ. Garcia JA, et al. Among authors: park jw. BJU Int. 2007 Mar;99(3):519-24. doi: 10.1111/j.1464-410X.2007.06659.x. BJU Int. 2007. PMID: 17407512

7

Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.

Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R. Park JW, et al. J Clin Oncol. 2007 Aug 20;25(24):3680-7. doi: 10.1200/JCO.2006.10.5718. J Clin Oncol. 2007. PMID: 17704416 Clinical Trial.

8

A role for biomarkers in the screening and diagnosis of breast cancer in younger women.

Esserman LJ, Shieh Y, Park JW, Ozanne EM. Esserman LJ, et al. Among authors: park jw. Expert Rev Mol Diagn. 2007 Sep;7(5):533-44. doi: 10.1586/14737159.7.5.533. Expert Rev Mol Diagn. 2007. PMID: 17892362 Review.

9

A comparison of RNA amplification techniques at sub-nanogram input concentration.

Lang JE, Magbanua MJ, Scott JH, Makrigiorgos GM, Wang G, Federman S, Esserman LJ, Park JW, Haqq CM. Lang JE, et al. Among authors: park jw. BMC Genomics. 2009 Jul 20;10:326. doi: 10.1186/1471-2164-10-326. BMC Genomics. 2009. PMID: 19619282 Free PMC article.

10

Disseminated tumor cells: the method is the message.

Park JW. Park JW. Breast Cancer Res Treat. 2011 Feb;125(3):739-40. doi: 10.1007/s10549-010-1107-5. Epub 2010 Aug 11. Breast Cancer Res Treat. 2011. PMID: 20700647 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,068 results

Search Page

Filters